GeoVax Labs, Inc. (GOVX) News

GeoVax Labs, Inc. (GOVX): $0.86

-0.17 (-16.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GOVX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 397

in industry

Filter GOVX News Items

GOVX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GOVX News Highlights

  • GOVX's 30 day story count now stands at 3.
  • Over the past 15 days, the trend for GOVX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about GOVX are BIO.

Latest GOVX News From Around the Web

Below are the latest news stories about GeoVax Labs Inc that investors may wish to consider to help them evaluate GOVX as an investment opportunity.

GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update

Conference call to be held Wednesday, March 9, at 4:30 p.m. Eastern Time Atlanta, GA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report 2021 financial results on Wednesday, March 9, 2022 after the market closes. Management will host a conference call at 4:30 p.m. ET on Wednesday, March 9, 2022 to review financial results

Yahoo | February 23, 2022

GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100

Atlanta, GA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announced today that its Chairman & CEO, David Dodd, has been selected as a 2022 Georgia Titan 100. The Titan 100 program recognizes Georgia’s Top 100 CEOs & C-level executives. They represent the state’s most accomplished business leaders in their respective industry demonstrating exceptional

Yahoo | February 22, 2022

GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference

Atlanta, GA, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chairman and CEO, David Dodd, will present a company overview at the 2022 BIO CEO & Investor Digital Conference taking place February 14-17, 2022. At the conference, Mr. Dodd will provide an overview of GeoVax’s product development programs, including updates on its ongoing Phase

Yahoo | February 8, 2022

GeoVax Announces Closing of $10 Million Private Placement

Atlanta, GA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today the closing of its previously announced private placement for the issuance and sale of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock, and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. Each share of common

Yahoo | January 20, 2022

GeoVax Labs to raise ~$10M via private offering of shares, warrants

GeoVax Labs (GOVX) is raising ~$10M from a single institutional investor through a private placement of ~707K common shares, 236K pre-funded warrants to buy common stock and

Seeking Alpha | January 14, 2022

ATI Physical, Cardiovascular Systems top healthcare gainers; Acutus, GeoVax among losers

ATI Physical Therapy (ATIP) +16%. Cardiovascular Systems (CSII) +14%. Acutus Medical (AFIB) -9%. GeoVax Labs (GOVX) -9%.

Seeking Alpha | January 14, 2022

GeoVax Announces $10 Million Private Placement

Atlanta, GA, Jan. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase

Yahoo | January 14, 2022

GeoVax retains CATO SMS for phase 1/2 trial of Gedeptin in head, neck cancer

GeoVax Labs <> retained CATO SMS to manage GeoVax’s ongoing phase 1/2 trial of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell…

Seeking Alpha | January 13, 2022

GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial

Activities Underway to Expand and Accelerate Enrollment of Ongoing Study for Head and Neck Cancer ATLANTA, GA, Jan. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the engagement of CATO SMS to manage GeoVax’s ongoing Phase 1/2 trial, evaluating the safety and efficacy of repeat cycles of Gedeptin® therapy in patients with recurrent head and neck squamo

Yahoo | January 13, 2022

GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer

Atlanta, GA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Company’s Chief Medical Officer (CMO). Dr. McKee brings over 30 years of experience in research and development, with specific expertise in vaccines, emerging diseases, biodefense, and respiratory viral infections. His

Yahoo | January 11, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5099 seconds.